OBIO
Price:
$5.46
Market Cap:
$206.52M
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue S...[Read more]
Industry
Biotechnology
IPO Date
2020-08-04
Stock Exchange
NASDAQ
Ticker
OBIO
According to Orchestra BioMed Holdings, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -3.50. This represents a change of -27.90% compared to the average of -4.85 of the last 4 quarters.
The mean historical PE Ratio of Orchestra BioMed Holdings, Inc. over the last ten years is -7.96. The current -3.50 PE Ratio has changed 4.30% with respect to the historical average. Over the past ten years (40 quarters), OBIO's PE Ratio was at its highest in in the March 2024 quarter at -3.29. The PE Ratio was at its lowest in in the December 2021 quarter at -585.54.
Average
-7.96
Median
-7.57
Minimum
-12.27
Maximum
-4.45
Discovering the peaks and valleys of Orchestra BioMed Holdings, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 38.75%
Maximum Annual PE Ratio = -4.45
Minimum Annual Increase = -50.31%
Minimum Annual PE Ratio = -12.27
Year | PE Ratio | Change |
---|---|---|
2023 | -6.18 | 38.75% |
2022 | -4.45 | -50.31% |
2021 | -8.96 | -26.98% |
The current PE Ratio of Orchestra BioMed Holdings, Inc. (OBIO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-6.53
5-year avg
-7.96
10-year avg
-7.96
Orchestra BioMed Holdings, Inc.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Orchestra BioMed Holdings, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Orchestra BioMed Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Orchestra BioMed Holdings, Inc.'s PE Ratio?
How is the PE Ratio calculated for Orchestra BioMed Holdings, Inc. (OBIO)?
What is the highest PE Ratio for Orchestra BioMed Holdings, Inc. (OBIO)?
What is the 3-year average PE Ratio for Orchestra BioMed Holdings, Inc. (OBIO)?
What is the 5-year average PE Ratio for Orchestra BioMed Holdings, Inc. (OBIO)?
How does the current PE Ratio for Orchestra BioMed Holdings, Inc. (OBIO) compare to its historical average?